Published in J Virol on September 01, 1997
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev (2010) 3.27
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A (2000) 3.10
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol (1997) 2.51
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol (1998) 2.38
Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol (2001) 2.32
Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J Virol (1999) 2.24
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol (1999) 2.23
Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A (2000) 2.16
Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol (1998) 1.90
HIV and the chemokine system: 10 years later. EMBO J (2006) 1.88
Antigenically distinct conformations of CXCR4. J Virol (2001) 1.74
Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol (1999) 1.72
A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med (1997) 1.70
The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc Natl Acad Sci U S A (1998) 1.65
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol (2010) 1.47
An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol (1998) 1.45
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol (1998) 1.43
Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J Virol (2000) 1.39
Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. J Virol (1998) 1.36
N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol (2000) 1.32
Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. J Virol (1998) 1.30
Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol (1998) 1.28
Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol (2000) 1.27
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25
Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence. Proc Natl Acad Sci U S A (2002) 1.25
A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses. J Virol (2000) 1.24
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol (2010) 1.23
Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol (2004) 1.17
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci U S A (1999) 1.14
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol (2011) 1.12
Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS One (2008) 1.10
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08
Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc (2009) 1.07
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates. J Virol (2002) 1.04
CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains. J Virol (1999) 1.04
Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J Virol (2009) 1.03
A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. J Exp Med (1998) 1.01
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol (2004) 1.01
Novel approaches to inhibit HIV entry. Viruses (2012) 1.00
HIV-1 Entry, Inhibitors, and Resistance. Viruses (2010) 1.00
The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc Natl Acad Sci U S A (1998) 0.99
Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol (2009) 0.97
Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors. J Virol (2001) 0.96
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120. Biochemistry (2009) 0.95
Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. J Virol (2003) 0.95
Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies. J Mol Model (2003) 0.94
CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm. Retrovirology (2013) 0.94
Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages. J Virol (2011) 0.93
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol (2012) 0.92
CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain. J Virol (2001) 0.91
Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J Biol Chem (2012) 0.89
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs. Curr Neuropharmacol (2007) 0.88
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS One (2014) 0.88
CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection. J Virol (1999) 0.87
CCR5 monoclonal antibodies for HIV-1 therapy. Curr Opin HIV AIDS (2009) 0.87
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses (2012) 0.86
CCR5 interactions with the variable 3 loop of gp120. J Mol Model (2006) 0.84
CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses. PLoS One (2013) 0.83
The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. Retrovirology (2007) 0.82
Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist. J Virol (2010) 0.82
Contrasting use of CCR5 structural determinants by R5 and R5X4 variants within a human immunodeficiency virus type 1 primary isolate quasispecies. J Virol (2003) 0.81
Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology (2010) 0.79
Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) (2012) 0.79
Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1. J Virol (1998) 0.79
An extended CCR5 ECL2 peptide forms a helix that binds HIV-1 gp120 through non-specific hydrophobic interactions. FEBS J (2015) 0.78
Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies. Antimicrob Agents Chemother (2009) 0.78
Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity. PLoS Pathog (2013) 0.78
Modeling of human CCR5 as target for HIV-I and virtual screening with marine therapeutic compounds. Bioinformation (2008) 0.78
Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. J Transl Med (2011) 0.76
Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1. AIDS Res Hum Retroviruses (2015) 0.75
The regulation of inflammatory pathways and infectious disease of the cervix by seminal fluid. Patholog Res Int (2014) 0.75
Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors. Org Biomol Chem (2013) 0.75
Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies. AIDS Res Hum Retroviruses (2015) 0.75
The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1. Front Immunol (2017) 0.75
A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem (1985) 90.20
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol (1994) 4.65
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science (1996) 4.39
Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry (1996) 4.35
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol (1993) 4.22
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19
Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science (1996) 3.84
Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol (1992) 3.53
Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell (1996) 3.44
A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol (1996) 3.26
Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol (1990) 3.07
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol (1994) 3.01
Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol (1993) 2.70
Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature (1988) 2.66
HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem (1997) 2.55
Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. Proc Natl Acad Sci U S A (1995) 2.46
Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci U S A (1997) 2.34
Rhodopsin mutants that bind but fail to activate transducin. Science (1990) 2.16
Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci U S A (1997) 2.11
The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Virology (1993) 2.05
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol (1996) 1.94
Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci U S A (1997) 1.91
Structure and function in rhodopsin. Studies of the interaction between the rhodopsin cytoplasmic domain and transducin. J Biol Chem (1992) 1.82
Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci U S A (1994) 1.73
Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol (1991) 1.67
The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J Biol Chem (1996) 1.58
Selective G protein coupling by C-C chemokine receptors. J Biol Chem (1996) 1.46
Partial functional mapping of the human interleukin-8 type A receptor. Identification of a major ligand binding domain. J Biol Chem (1993) 1.30
The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. J Biol Chem (1994) 1.24
Site-directed mutagenesis of human beta-adrenergic receptors: substitution of aspartic acid-130 by asparagine produces a receptor with high-affinity agonist binding that is uncoupled from adenylate cyclase. Proc Natl Acad Sci U S A (1988) 1.23
Human immunodeficiency virus infection is efficiently mediated by a glycolipid-anchored form of CD4. Proc Natl Acad Sci U S A (1990) 1.22
Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization. J Biol Chem (1996) 1.21
Homologous desensitization of HEL cell thrombin receptors. Distinguishable roles for proteolysis and phosphorylation. J Biol Chem (1992) 1.15
Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis (1995) 1.09
Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions. Biochemistry (1995) 1.03
BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Blood (1995) 1.01
Interleukin-8 receptor beta. The role of the carboxyl terminus in signal transduction. J Biol Chem (1995) 1.00
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 6.52
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity (1995) 5.77
A new classification for HIV-1. Nature (1998) 5.30
Assembly of influenza hemagglutinin trimers and its role in intracellular transport. J Cell Biol (1986) 4.93
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A (1999) 4.61
Regulation of protein export from the endoplasmic reticulum. Annu Rev Cell Biol (1988) 4.53
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J Cell Biol (1993) 4.34
Membrane fusion activity of the influenza virus hemagglutinin. The low pH-induced conformational change. J Biol Chem (1985) 4.32
Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler (1994) 4.09
Protein-mediated membrane fusion. Annu Rev Biophys Biophys Chem (1989) 3.99
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Studies on the mechanism of membrane fusion: site-specific mutagenesis of the hemagglutinin of influenza virus. J Cell Biol (1986) 3.56
Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell (1996) 3.44
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol (1996) 3.26
DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol (2001) 2.95
Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A (1999) 2.88
The bulk-flow hypothesis: not quite the end. Trends Cell Biol (1995) 2.87
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A (2001) 2.86
Characterization of a mouse monoclonal antibody specific for O-linked N-acetylglucosamine. Anal Biochem (2001) 2.58
Heavy chain binding protein recognizes incompletely disulfide-bonded forms of vesicular stomatitis virus G protein. J Biol Chem (1990) 2.56
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood (1997) 2.55
Quaternary structure of influenza virus hemagglutinin after acid treatment. J Virol (1986) 2.54
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol (1997) 2.51
cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J Virol (2001) 2.50
Expression of Xa1, a bacterial blight-resistance gene in rice, is induced by bacterial inoculation. Proc Natl Acad Sci U S A (1998) 2.49
Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers. J Cell Biol (1988) 2.48
Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem (2000) 2.42
Nucleus accumbens oxytocin and dopamine interact to regulate pair bond formation in female prairie voles. Neuroscience (2003) 2.35
CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr Biol (1997) 2.35
Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci U S A (1997) 2.34
Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology (1997) 2.26
Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J Virol (1999) 2.24
CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A (1997) 2.23
Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest (1989) 2.23
From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood (1997) 2.23
Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65. J Virol (1994) 2.17
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med (1997) 2.15
Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci U S A (1997) 2.11
Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol (1997) 2.10
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A (1994) 2.09
Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol (1997) 2.08
Dissected nucleus-independent chemical shift analysis of pi-aromaticity and antiaromaticity. Org Lett (2001) 2.01
Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol (1998) 2.01
Variant influenza virus hemagglutinin that induces fusion at elevated pH. J Virol (1986) 2.00
Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem (1997) 1.98
Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol (2000) 1.95
The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med (1995) 1.95
Conformational changes and fusion activity of influenza virus hemagglutinin of the H2 and H3 subtypes: effects of acid pretreatment. J Virol (1990) 1.91
Patterns of brain vasopressin receptor distribution associated with social organization in microtine rodents. J Neurosci (1994) 1.90
Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol (1998) 1.89
ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol (1998) 1.88
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol (1999) 1.80
Chlorinated indium tin oxide electrodes with high work function for organic device compatibility. Science (2011) 1.76
CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood (1999) 1.75
Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol (1999) 1.75
Antigenically distinct conformations of CXCR4. J Virol (2001) 1.74
Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem (2000) 1.73
General method for the identification of plasmid species in fast-growing soil microorganisms. Appl Environ Microbiol (1985) 1.73
Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol (1999) 1.72
A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med (1997) 1.70
Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol (1999) 1.68
Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer (1995) 1.66
Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol (2001) 1.66
HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol (2006) 1.65
Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood (2000) 1.65
Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis (1994) 1.64